ArticleEuropean thyroid journal2026
Assessing the sodium-iodide symporter (NIS) in pediatric differentiated thyroid carcinoma.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting radioiodine therapy response in advanced and recurrent thyroid cancer.Endocrine-related cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The sodium-iodide symporter (NIS), encoded by the SLC5A5 gene, is essential for iodide uptake and the effectiveness of radioiodide therapy in differentiated thyroid carcinoma (DTC). Data addressing the relationship between NIS transcription and protein expression in pediatric DTC remain limited. Methods: We conducted a retrospective cohort study of pediatric and adolescent patients with DTC, evaluating NIS protein expression by immunohistochemistry in tumor and adjacent nontumoral thyroid tissues and tumor SLC5A5 mRNA expression by quantitative real-time PCR. Clinical, pathological, molecular, and treatment-related variables were analyzed. Results: We analyzed DTC samples from 92 patients diagnosed under the age of 19. NIS was present at significantly lower levels in tumor cells than in adjacent nontumoral cells (odds ratio (OR): 106.8; 95% (CI): 30.7-337.5; P < 0.0001). NIS was only detected in 20/92 of tumor samples, while SLC5A5 was expressed in 36/70 of tumor samples. No associations were found between NIS expression or SLC5A5 expression and clinical or histological features, metastasis, iodide-131 (I-131) activity, or treatment response. A dissociation between gene expression and protein detection was observed. Despite reduced tumoral NIS protein expression, most patients achieved an excellent response to radioiodide therapy. Conclusion: This study highlights significant differences in NIS expression between pediatric thyroid tumors and adjacent nontumoral tissue, with a lower proportion of NIS-positive tumors compared with SLC5A5-high cases. No associations were observed between NIS protein detection or SLC5A5 expression and clinical features, histology, tumor aggressiveness, or treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.